What is KALA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KALA?

P/E (TTM) is n/a and 52-week range is $0.29 to $95.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KALA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KALA?

The company profile lists revenue (TTM) near $6M, net income (TTM) near $-8.18B, EPS (TTM) near $-72.45 when available from the market-data feed. Figures are informational and may lag live markets.

Where is KALA BIO Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Arlington, Massachusetts, US, 19.3M shares outstanding, ISIN US4831192020 when available from company profile and filing metadata.

KALA BIO Inc

$KALA

Health Care · Biotechnology

IR Run Scenarios

$0.29

-0.89%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Kala Bio, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Employees

Website

www.kalarx.com/

IPO

2017-07-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)